Last updated: February 15, 2026
Overview
NDC 59676-0800 corresponds to Apretude (cabotegravir extended-release injectable suspension). Approved by the FDA in December 2021, Apretude is indicated for HIV-1 prevention. The drug is marketed by ViiV Healthcare and is positioned as a long-acting injectable, with administration every two months.
Market context
The global HIV prevention market has experienced steady growth driven by increasing recognition of injectable prophylactics, especially in high-risk populations. The market appeal of Apretude stems from its dosing schedule, which enhances adherence over daily oral regimens (e.g., Truvada or Descovy). In 2022, the global HIV prevention market was valued at approximately $1.2 billion and is projected to reach $2.3 billion by 2030, growing at a CAGR of roughly 8%.
Current sales and adoption
As of late 2022, Apretude's U.S. utilization remains moderate, with initial uptake concentrated among high-risk populations such as men who have sex with men (MSM) and individuals with high adherence challenges. ViiV Healthcare has reported sales of approximately $50 million for the product in 2022, with specific regional adoption rates varying across states based on healthcare infrastructure and insurance coverage.
Competitive landscape
Apretude's primary competition includes daily oral pre-exposure prophylaxis (PrEP) agents such as Descovy and Truvada. The long-acting injectable paradigm faces competition from experimental agents and potential future formulations. Its unique selling point remains dosing convenience, which could limit decline in market share if adherence issues persist with oral options.
Pricing structure and reimbursement
The wholesale acquisition cost (WAC) for Apretude was set at approximately $3,200 per five-dose schedule in 2022, equivalent to $640 per dose. Payers typically negotiate discounts, and the average sale price (ASP) in the healthcare sector tends to be 20-30% lower than WAC.
Insurance coverage policies have started adopting Apretude with prior authorization. Medicaid programs in several states have included it, expanding access. Reimbursement rates vary, but preliminary estimates suggest average reimbursed prices around $2,200-$2,400 per course.
Price projections
Considering the current market dynamics, anticipated growth, and competition, the following projections apply:
| Year |
Estimated Price Range (per course) |
Notes |
| 2023 |
$2,200 - $2,400 |
Stabilizes with widespread payer adoption. Potential discounts for bulk or negotiated sales. |
| 2024 |
$2,100 - $2,300 |
Slight decline driven by increased competition and generic options if regulatory pathways emerge. |
| 2025 |
$2,000 - $2,200 |
Flat or declining trend as market matures; potential price pressures from new entrants. |
| 2026 |
$1,900 - $2,100 |
Continued decline expected if patent challenges or biosimilars enter the market. |
Market expansion factors
- Regulatory approvals outside the U.S. are pending or in progress, which could expand the target market, potentially increasing sales volume but not directly impacting per-course pricing immediately.
- Long-term demand depends heavily on public health campaigns, insurance adoption, and clinician prescribing patterns.
- Pricing pressure from potential biosimilar or generic entries remains a risk after the product’s patent expires (likely around 2031, given current patent protections).
Impact of new competitors
The pipeline includes several investigational long-acting PrEP agents, such as lenacapavir and other injectables in Phase 3. Market share could shift if these drugs demonstrate superior efficacy, safety, or cost advantages. Aprelude’s moderate market entry and clinical profile position it well for sustained relevance, but pricing may need to adjust as competition intensifies.
Implications for stakeholders
- ViiV Healthcare may need to consider tiered pricing strategies and patient assistance programs to maintain uptake as competition increases.
- Payers and providers will pressure for lower reimbursement rates to contain costs.
- Investors should monitor regulatory and patent developments, as these significantly influence pricing power.
Summary
Apretude is positioned within a growing HIV prevention market, with current pricing around $2,200-$2,400 per course. Market expansion is expected to slowly increase sales volumes, but pricing will likely face downward pressure over the next three years due to competitive and policy factors. Long-term prices are projected to decline gradually, influenced by regulatory, clinical, and economic factors.
Key Takeaways
- Apretude’s 2022 initial sales were approximately $50 million; its price per course is around $2,200-$2,400.
- The HIV prevention market is projected to grow at a CAGR of 8%, reaching $2.3 billion by 2030.
- Price trends over the next three years are expected to decline from current levels due to competitive pressures.
- Expanded regulatory approvals internationally may increase volume but won't significantly impact per-course pricing immediately.
- Patent and biosimilar entries could influence long-term pricing strategies.
FAQs
1. What factors influence the price of Apretude?
Pricing is affected by manufacturer negotiations, payer coverage policies, competition from other PrEP options, and regulatory or patent challenges.
2. Can the price of Apretude decrease rapidly?
Price reductions are gradual, driven by market maturation, increased competition, and healthcare policy pressures, typically over several years.
3. How does Apretude’s pricing compare to oral PrEP?
Over a 12-month period, Apretude's per-course cost (~$2,200-$2,400) may be comparable to or slightly higher than oral regimens (~$1,600-$2,000), but offers adherence advantages.
4. What are the main risks to price stability?
Entry of biosimilars, loss of patent protection, and shifts in healthcare policy could lead to price erosion.
5. When might biosimilar competitors appear?
Patents are likely to expire around 2031; biosimilars could enter within 1-3 years afterward, impacting pricing.
Sources
- ViiV Healthcare. Apretude (cabotegravir) prescribing information. December 2021.
- MarketResearch.com. HIV prevention market analysis and forecasts, 2022.
- Centers for Medicare & Medicaid Services. Physician Fee Schedule Search.
- IQVIA. Global HIV/AIDS therapeutics market report, 2022.
- FDA. Approved drugs and patent information for cabotegravir.
